Compare Amazon.com Inc (AMZN) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amazon.com Inc vs Quest Diagnostics Inc — how do they compare? Amazon.com Inc trades at $246.18 (market cap $2.64T), while Quest Diagnostics Inc trades at $209.42 (market cap $22.96B). The key difference: Amazon.com Inc is far larger — about 115× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays a 1.66% dividend while Amazon.com Inc pays none. Which is the better fit depends on your goals.
| AMZN | DGX | |
|---|---|---|
Market Cap | $2.64T | $22.96B |
Volume | 3,931,282 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $274.95 | $216.02 |
52-Week Low | $198.79 | $166.42 |
Enterprise Value | $2.71T | $28.98B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amazon (AMZN) trades at $244.19, down 0.47% on the day but maintains strong bullish technical momentum with support at $241. The company demonstrates robust fundamentals with 2025 revenue of $716.92B and net income of $77.67B, representing 10.83% profit margin. Recent Q1 2026 earnings beat expectations with EPS of $2.78 versus $1.63 expected, while analyst consensus remains overwhelmingly positive with 88.3% buy ratings.
Amazon's outlook remains favorable with continued revenue growth and expanding profitability, though significant capital expenditures for AI infrastructure and competitive pressures in e-commerce present risks. The stock trades at a P/E of 29.35, offering growth potential relative to the consensus price target of $320.75, representing 31% upside from current levels.
Quest Diagnostics (DGX) trades at $207.44, down 0.29% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported $11.04B revenue in 2025 with a 9.08% net margin, supported by strong cash flow from operations of $1.89B. Recent news highlights expansion of oncology testing services, including New York State approval for Haystack MRD, enhancing its diagnostic portfolio.
DGX offers steady growth with a consensus price target of $226, implying 9% upside. Risks include rising debt levels and healthcare policy uncertainties, but analyst sentiment leans positive with 38% buy ratings. The stock's valuation at a P/E of 22.92 appears reasonable given its profitability and market position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amazon.com Inc
Amazon.com, Inc. is an online retailer that offers a wide range of products. The Company products include books, music, computers, electronics and numerous other products. Amazon offers personalized shopping services, Web-based credit card payment, and direct shipping to customers. Amazon also operates a cloud platform offering services globally.
Read more on AMZN →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
